Changes in Beneficial Ownership · 4
STAAR Surgical Company
STAANASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-08-14
- Issuer
- STAAR SURGICAL CO
- Issuer CIK
- 0000718937
- Trading symbol
- STAA
Reporting owner 1
- Name
- Foust Warren
- Reporting owner CIK
- 0001970778
- Relationship
- Officer
- Officer title
- President and CEO
- Address
- 25510 COMMERCENTRE DRIVE, LAKE FOREST, CA, 92630
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-08-14 | M · Form 4 | 7,331 | A | 0 | 93,887 | D |
| Common Stock | 2026-08-14 | F · Form 4 | 3,730[F1] | D | 26.18 | 97,617 | D |
| Common Stock | 2026-08-14 | M · Form 4 | 3,666 | A | 0 | 93,951 | D |
| Common Stock | 2026-08-14 | F · Form 4 | 1,865[F2] | D | 26.18 | 95,816 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
- F · Form 4
- Securities delivered or withheld for exercise price or tax liability under Rule 16b-3
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock Units | 0[F3] | 2026-08-14 | A · Form 4 | 22,493 | A | 0 | [F4] | [F4] | Common Stock | 22,493 | 22,493 | D |
| Stock Option (right to buy) | 26.18 | 2026-08-14 | A · Form 4 | 40,471 | A | 0 | [F5] | 2036-08-13 | Common Stock | 40,471 | 40,471 | D |
| Stock Option (right to buy) | 26.18 | 2026-08-14 | A · Form 4 | 37,962 | A | 0 | [F6] | 2036-08-13 | Common Stock | 37,962 | 37,962 | D |
| Performance Stock Option (right to buy) | 26.18 | 2026-08-14 | A · Form 4 | 131,830 | A | 0 | [F7] | 2036-08-13 | Common Stock | 131,830 | 131,830 | D |
| Performance Stock Option (right to buy) | 26.18 | 2026-08-14 | A · Form 4 | 123,659 | A | 0 | [F8] | 2036-08-13 | Common Stock | 123,659 | 123,659 | D |
| Performance Stock Units | 0 | 2026-08-14 | M · Form 4 | 7,331 | A | 0 | [F9] | 2027-12-31 | Common Stock | 7,331 | 93,887 | D |
| Performance Stock Units | 0 | 2026-08-14 | M · Form 4 | 3,666 | A | 0 | [F10] | 2027-12-31 | Common Stock | 3,666 | 97,553 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
Footnotes
- F1
- On August 14, 2026, the third tranche of 7,331 performance stock units ("PSUs") awarded to the Reporting Person under the Issuer's 2025 Performance Stock Award Program ("2025 PSU Program") in connection with his annual equity grant vested, of which 3,730 shares were withheld to satisfy taxes.↩ 1
- F2
- On August 14, 2026, the third tranche of 3,666 PSUs awarded to the Reporting Person under the Issuer's 2025 PSU Program in connection with his expanded role as President and Chief Operating Officer vested, of which 1,865 shares were withheld to satisfy taxes.↩ 1
- F3
- Each RSU represents the right to receive one share of the Corporation's common stock upon vesting.↩ 1
- F4
- The Reporting Person was granted Issuer restricted stock units (RSUs) on August 14, 2026 (the "Grant Date"). These RSUs vest as to 1/3 on the first anniversary of the Grant Date, and the remaining 2/3 vesting in 24 substantially equal monthly installments thereafter.↩ 1↩ 2
- F5
- The Reporting Person was granted an option to purchase 40,471 shares of Company common stock. The shares underlying the option vest over three years from the Grant Date, with one-third vesting on the first anniversary of the Grant Date and the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter↩ 1
- F6
- The Reporting Person was granted an option to purchase 37,962 shares of Company common stock. The shares underlying the option vest over 42 months from the Grant Date, with one-third vesting on the 18-month anniversary of the Grant Date and the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter.↩ 1
- F7
- The Reporting Person was granted a performance option to purchase 131,830 shares of Company common stock. The shares underlying the option vest over a performance period ending on the earlier of a change in control and the 10-year anniversary of the Grant Date, subject to achievement of stock-price hurdles of $50.00, $75.00 and $100.00 per share, and time vest as to one-third on the first anniversary of the Grant Date with the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter.↩ 1
- F8
- The Reporting Person was granted a performance option to purchase 123,659 shares of Company common stock. The shares underlying the option vest over a performance period ending on the earlier of a change in control and the 10-year anniversary of the Grant Date, subject to achievement of stock-price hurdles of $50.00, $75.00 and $100.00 per share, and time vest as to one-third on the 18-month anniversary of the Grant Date with the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter.↩ 1
- F9
- Represents the settlement of the third tranche of PSUs awarded to the Reporting Person in connection with his annual equity grant under the 2025 PSU Program. The number of shares was determined upon certification by the Compensation Committee based on achievement of applicable performance goals. The original grant was exempt pursuant to Rule 16b-3(d) and was not previously reported.↩ 1
- F10
- Represents the settlement of the third tranche of PSUs awarded under the 2025 PSU Program to the Reporting Person in connection with his expanded role as President & Chief Operating Officer. The number of shares earned was determined upon certification by the Compensation Committee based on achievement of applicable performance goals. The original grant was exempt pursuant to Rule 16b-3(d) and was not previously reported.↩ 1
Signature 1
- Signed
- /s/ Warren Foust
- Date
- 2026-08-18
Company context
STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for over 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer® Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICLs are clinically proven to deliver safe long-term vision correction without removing corneal tissue or the eye's natural crystalline lens. Its EVO ICL™ product line provides visual freedom through a quick, minimally invasive procedure.
Current securities
Recent company filings
- SCHEDULE 13G/A - filed by Point72 Asset Management, L.P. regarding STAAR SURGICAL CONov 16, 2026
- 10-Q filingNov 4, 2026
- Results of Operations and Financial Condition · Regulation FD DisclosureNov 4, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureOct 5, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureSep 10, 2026